Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CARE RatingsBOM:534804 +1.00%81 EBITDA Margin % is 58.51% as of Mar. 2026, which is 14% above its 10-year median of 51.23. GuruFocus rates BOM:534804 with a GF Score™ of 81/100 and a GF Value™ of ₹1,709.11 (Fairly Valued). The stock has 1 warning sign investors should review. Among 671 Capital Markets companies, CARE Ratings ranks better than 71.39% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. CARE Ratings's EBITDA for the
three
months ended in Mar. 2026 was ₹765 Mil. CARE Ratings's Revenue for the
three
months ended in Mar. 2026 was ₹1,307 Mil. Therefore, CARE Ratings's EBITDA margin for the quarter that ended in Mar. 2026 was 58.51%.
CARE Ratings (BOM:534804) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
CARE Ratings EBITDA Margin % Related Terms
CARE Ratings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for CARE Ratings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:534804 vs SPGI, CME, ICE: EBITDA Margin % Comparison
For the Financial Data & Stock Exchanges subindustry, CARE Ratings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CARE Ratings EBITDA Margin % vs Capital Markets Industry
For the Capital Markets industry and Financial Services sector, CARE Ratings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where CARE Ratings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CARE Ratings (BOM:534804) has a EBITDA Margin % of 58.51% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CARE Ratings and its competitors. This is 14% above median its historical median of 51.23. Over the past decade, CARE Ratings' EBITDA Margin % has ranged from 43.13 to 71.82. According to the industry distribution chart, CARE Ratings ranks #192 out of 671 companies in the Capital Markets industry, placing it in the top 28.6%.
Is CARE Ratings' EBITDA Margin % too high?
CARE Ratings' current EBITDA Margin % of 58.51% is 14% above median its 10-year median of 51.23. Over the past 10 years, this metric has ranged from a low of 43.13 to a high of 71.82. The Capital Markets industry median EBITDA Margin % is 22.10. CARE Ratings' value of 58.51% is 164.8% above this industry median. Based on the distribution chart, CARE Ratings ranks #192 out of 671 companies in the Capital Markets industry, which is above the industry midpoint. Overall, CARE Ratings has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does CARE Ratings' EBITDA Margin % compare to SPGI and CME?
According to the Capital Markets industry distribution chart, CARE Ratings ranks #192 out of 671 companies for EBITDA Margin %. This puts CARE Ratings in the upper half of its industry. The industry median EBITDA Margin % is 22.10. CARE Ratings' value of 58.51% is 164.8% above this benchmark. Historically, CARE Ratings' own EBITDA Margin % has ranged from 43.13 to 71.82 over the past decade. While the company's 10-year median is 51.23 vs. the industry median of 22.10, CARE Ratings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Capital Markets company?
The median EBITDA Margin % among Capital Markets companies is 22.10, based on 671 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CARE Ratings's current EBITDA Margin % of 58.51% is 164.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CARE Ratings and its competitors. For the Capital Markets industry, the median EBITDA Margin % is 22.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CARE Ratings's current EBITDA Margin % is 58.51%, which is 14% above median its own 10-year median of 51.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARE Ratings stock overvalued right now?
Based on GuruFocus' analysis, CARE Ratings (BOM:534804) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,709.11, compared to a current price of ₹1,746.10 — trading 2.2% above its estimated fair value. The current EBITDA Margin % is 58.51%, which is 14% above median its 10-year median of 51.23 and 164.8% above the Capital Markets industry median of 22.10. CARE Ratings' overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For CARE Ratings (BOM:534804), the current EBITDA Margin % is 58.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CARE Ratings (BOM:534804) Overvalued in 2026?
Based on GuruFocus' analysis, CARE Ratings stock appears to be overvalued.
The current stock price of ₹1,746.10 is trading 2.2% above its estimated GF Value™ of ₹1,709.11.
GuruFocus considers CARE Ratings to be Fairly Valued.
Key valuation signals for BOM:534804:
EBITDA Margin %: 58.51% (14% above median its 10-year median of 51.23)
GF Value™: ₹1,709.11 vs. price of ₹1,746.10 (2.2% above fair value)
Industry Position: 164.8% above the Capital Markets median (#192 of 671)
No single metric tells the full story. See the BOM:534804 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CARE Ratings Ltd provides various credit ratings that helps corporates to raise capital for their various requirements and assists the investors to form an informed investment decision based on the credit risk and their own risk-return expectations. The company works in Bank Loan Ratings; Capital Market Instruments, Including NCDs/ Bonds/ Hybrids/ CPs/CDs, etc; Structured Finance Ratings; Monitoring Agency Services for Equity Capital; Rating of REITs /InvITs; Resolution Plan Ratings; Recovery Ratings; Issuer Ratings. The company's segment includes Ratings and related services; and Others. The company generates majority of revenue from Ratings and related services. The company has presence in India, and Outside India. It generates majority of revenue from India.
81GF Score
Get the complete analysis for BOM:534804
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:534804 has been successfully added to your 
